Market Overview

Amarin Shares Up 5% as FDA Says October 16th Advisory Committee Meeting Will Take Place as Scheduled

Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that it was notified by the U.S. Food and Drug Administration (FDA) that the scheduled advisory committee meeting to be held on October 16, 2013 in connection with the proposed Vascepa® (icosapent ethyl) ANCHOR indication will take place as scheduled despite the current Federal Government lapse in appropriations.

See full press release

Posted-In: News Guidance Contracts Asset Sales Management M&A Global

 

Related Articles (AMRN)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional